Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 5/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409411 | 1.00 | SLC7A5 (0.39) | SLC7A5F2PRSS1BMP1F10 | |
| SCHEMBL10170433 | 1.00 | SLC7A5 (0.39) | SLC7A5F2PRSS1BMP1F10 | |
| SCHEMBL407531 | 0.86 | SLC7A5 (0.39) | SLC7A5F2PRSS1BMP1F10 | |
| SCHEMBL9968916 | 0.86 | SLC7A5 (0.39) | SLC7A5F2PRSS1BMP1F10 | |
| SCHEMBL407530 | 0.86 | SLC7A5 (0.39) | SLC7A5F2PRSS1BMP1F10 | |
| SCHEMBL408595 | 0.84 | HDAC1 (0.41) | SLC7A5F2PRSS1BMP1L3MBTL1 | |
| SCHEMBL410763 | 0.84 | SLC7A5 (0.38) | SLC7A5F2PRSS1BMP1L3MBTL1 | |
| SCHEMBL410764 | 0.84 | SLC7A5 (0.38) | SLC7A5F2PRSS1BMP1L3MBTL1 | |
| SCHEMBL408596 | 0.84 | HDAC1 (0.41) | SLC7A5F2PRSS1BMP1L3MBTL1 | |
| SCHEMBL10170385 | 0.84 | SLC7A5 (0.38) | SLC7A5F2PRSS1BMP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414342-A1 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | SLC7A5 2990/4885F2 2321/4885PRSS1 4700/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | SLC7A5 2990/4885F2 2321/4885PRSS1 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.